When and how should anti‑deamidated gliadin peptide (anti‑DGP) antibodies be used in the evaluation of celiac disease?

Anti-Deamidated Gliadin Peptide (Anti-DGP) Antibodies in Celiac Disease Evaluation

Anti-DGP antibodies should be used as part of the initial serologic workup for suspected celiac disease, particularly IgA anti-DGP alongside tissue transglutaminase IgA (tTG-IgA), and IgG anti-DGP is essential for patients with IgA deficiency.

Primary Diagnostic Role

Initial Screening Strategy

The most recent guidelines establish that anti-DGP testing serves two critical functions in celiac disease diagnosis:

• For seronegative enteropathy evaluation: When celiac disease is suspected but initial serology is negative, comprehensive testing should include tTG-IgA, IgA anti-DGP, and endomysial antibody (EMA) IgA, along with total IgA measurement 1.

• For IgA deficiency: Patients with total IgA below the lower limit of detection who test positive for IgG tTG or IgG anti-DGP should be considered to have celiac disease with selective IgA deficiency rather than seronegative celiac disease 1.

Performance Characteristics

The diagnostic accuracy varies by antibody type:

• IgA anti-DGP: Shows 84.3% sensitivity and 79.8% specificity in adults 2. In children under 3 years, IgA anti-DGP demonstrates superior performance with 91.7% positive predictive value 3.

• IgG anti-DGP: Demonstrates 82.3% sensitivity but 98.9% specificity in adults 2, making it highly reliable when positive. In pediatric populations, IgG anti-DGP shows 95.4% sensitivity and 85.7% specificity 4.

Specific Clinical Scenarios

Children Under 3 Years Old

Anti-DGP testing is particularly valuable in young children, where it may outperform tTG-IgA:

• Both IgA anti-DGP and tTG-IgA should be obtained when screening infants and children under 3 years 3
• Anti-DGP antibodies can appear up to 1 year earlier than tTG antibodies in genetically susceptible children 5
• The combination provides 90.9% positive predictive value in this age group 3

IgA Deficiency

This is a critical indication where anti-DGP is mandatory:

• IgG anti-DGP (along with IgG tTG or IgG EMA) must be tested in patients with confirmed IgA deficiency 1, 6, 7
• IgG anti-DGP identified both cases with total IgA deficiency that were missed by IgA-based tests in one prospective study 2

Refractory or Non-Responsive Celiac Disease

When evaluating patients with persistent symptoms despite gluten-free diet:

• Serologic testing should include tTG-IgA, anti-DGP (IgA and IgG), and EMA to assess ongoing gluten exposure 6
• Elevated anti-DGP levels suggest persistent gluten ingestion, though negative results don't exclude intermittent exposure 6

Monitoring Established Disease

Anti-DGP antibodies are NOT recommended as the primary monitoring tool for established celiac disease on a gluten-free diet:

• Anti-DGP IgA performs similarly to tTG-IgA in monitoring dietary adherence, with comparable sensitivity (around 52-57%) for detecting transgressions 8
• tTG-IgA remains the preferred routine monitoring test 8
• Positive anti-DGP suggests poor adherence or contamination, but negative results cannot confirm strict compliance 8

Optimal Testing Algorithms

For Initial Diagnosis

Two-antibody approach for maximum accuracy:

1. Standard patients: Measure tTG-IgA + IgA anti-DGP simultaneously

   • If both positive at >10x upper limit of normal: 100% positive predictive value for Marsh 3 histology 9
   • Double positivity at >1x upper limit: 92.5% predictive of celiac disease 9

2. Suspected IgA deficiency: Measure total IgA, then if deficient, test IgG tTG + IgG anti-DGP 1, 2

For Seronegative Enteropathy

When villous atrophy is present but initial serology negative:

1. Measure total IgA level first
2. Test tTG-IgA, IgA anti-DGP, and EMA-IgA comprehensively 1
3. If IgA deficient, switch to IgG-based tests (tTG-IgG and IgG anti-DGP) 1
4. Consider HLA-DQ2/DQ8 testing if still negative to rule out celiac disease 1

Key Advantages Over Traditional Testing

Anti-DGP offers specific benefits that complement tTG testing:

• Cost-effectiveness: The combination of tTG-IgA and IgG anti-DGP can potentially replace the more expensive, operator-dependent EMA testing while maintaining 94% sensitivity and 100% specificity 10
• Earlier detection: Anti-DGP may become positive before tTG in children, allowing earlier diagnosis 5
• Severity correlation: Higher anti-DGP titers correlate with more severe intestinal damage 4, 11

Critical Pitfalls to Avoid

1. Do not use IgG anti-DGP in IgA-sufficient patients as a standalone test - it has lower sensitivity than IgA-based tests in this population 12, 13

2. Do not rely on anti-DGP alone for mass screening - tTG-IgA remains superior for general population screening with only marginal improvement when adding anti-DGP 11

3. Do not assume negative anti-DGP excludes celiac disease - sensitivity is lower than tTG-IgA, particularly in adults (84.3% vs 93.7%) 2

4. Do not use anti-DGP IgG for monitoring in IgA-sufficient patients - IgG tTG and anti-DGP often remain positive despite strict gluten-free diet adherence in IgA deficiency 8

5. Ensure patients are on gluten-containing diet - at least 3 slices of wheat bread daily for 1-3 months before testing if previously avoiding gluten 13

Evidence Quality Considerations

The strongest evidence comes from the 2021 AGA guidelines on seronegative enteropathies 1 and the 2024 Nature Reviews guidelines on monitoring 8, which provide the most current consensus. The 2022 systematic review 7 offers robust meta-analytic data on test performance. Recent prospective studies from 2024-2025 10, 9 demonstrate that the tTG/DGP combination approach can achieve diagnostic certainty without biopsy in select cases, though this remains an evolving area requiring careful patient selection.